As a new dual receptor (integrin Î ± vÎ23 and FAP) targeting PET radiotracer, 68Ga‐FAPI‐RGD is promising as an excellent imaging agent applicable to various cancers. In this research, we investigate the safety, biodistribution and radiation dosimetry of 68Ga‐FAPI‐RGD in healthy volunteers. Moreover, we evaluate the potential usefulness of 68Ga‐FAPI‐RGD positron emission tomography/computed tomography (PET/CT) for the diagnosis of primary and metastatic lesions in various types of cancer, and compared with 18F‐FDG PET/CT. This evidence concerns the gene FAP and cancer.